Therapeutic Response

CD22 + status confers therapeutic sensitivity to Bosutinib in patients with Chronic Myeloid Leukemia, BCR-ABL1+.

Statements

Source and description
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult patients with accelerated phase, and blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.
Bosulif (bosutinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized bosutinib as for the treatment of adult and pediatric patients aged 6 years and older with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitors and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options.